In clinical practice, PPARγ agonists such as pioglitazone and rosiglitazone have been used for a long time for the management of insulin resistance, which decreases the activation of MCP1, IL-6 and TNF and regulates the synthesis of adiponectin (anti-inflammatory molecule) [176,177]. The gene discussed is PPARG; the disease is Insulin resistance.